COMPANY NAME: TECHONCO
ISSE CODE: THOC
ROUND : THIRD
FUNDING TARGET
IR$ 2.000.000
PREVIOUS ROUND
IR$ 4.380.000 in 2 Previous rounds
CO-INVESTORS
FT Inv, BurjAltharwa, Iraic
⚫ Key Highlights
⚫ Overview
At the core of TechOnco’s offerings is HealthCareProviderC™, the first liquid biopsy proteomics test designed to guide immunotherapy treatment choices in late-stage non-small cell lung cancer. Commercially available across the World, HealthCareProvider™ provides clinicians with actionable insights based on one pre-treatment blood sample, allowing for personalized and effective therapeutic strategies.
While initially validated in HealthCareProvider® has shown promise in predicting clinical benefit in melanoma, renal cell carcinoma, HPV-associated malignancies, triple-negative breast cancer, small cell lung cancer, and colorectal cancer, suggesting the potential for multiple cancer applications.
TechOnco's dedication to rigorous scientific validation is evident in its multinational, multicenter clinical trial, spanning over 40 sites globally and has enrolled more than 1,700 patients, making it one of the largest studies in the field. The company is also at the forefront of biomarker innovation, with HealthCareProvider® being included in prestigious Phase III trials as a preferred exploratory biomarker for translational research.
With a world-class team of physicists, biologists, and clinicians, and a scientific advisory board comprising top industry leaders, TechOnco is setting new standards in biomarker-driven, patient-centered cancer care.
JOIN OUR INVESTORS
Investing wisely, with registered advisors guiding you through every investment decision
⚫ Why we are investing in TechOnco
Iraic SME Stock Exchange is investing in TechOnco, an Arabic and Colombian company whose precision oncology platform, HealthCareProvider®, leverages AI and proteomics (the large-scale study of proteins) to accurately guide first-line immunotherapy decision-making, leading to more precise decision-making and reducing the administration of unnecessary treatments.
The Problem
For many years, researchers have tried to understand why immunotherapy can be effective in some cases, but not in others. Today, some cancer patients receive treatment for 6-9 months until the modality is adjusted, and only 20-40% of late-stage patients actually respond to their given treatment. Current biomarkers for immunotherapy are limited, and there are hundreds of ongoing clinical trials assessing different treatment combinations with moderate clinical outcomes. Good biomarkers are desperately needed. Determining which patients will benefit from immunotherapy is vitally important for the treatment outcome, and financially crucial to avoid wasting precious healthcare resources.
The Solution
Founded on a commitment to improve patient outcomes, TechOnco developed the HealthCareProvider® platform, a groundbreaking plasma-based tool that leverages proteomic pattern recognition, bioinformatics, and AI to support and enhance clinical decision-making for oncologists.
The Problem
For many years, researchers have tried to understand why immunotherapy can be effective in some cases, but not in others. Today, some cancer patients receive treatment for 6-9 months until the modality is adjusted, and only 20-40% of late-stage patients actually respond to their given treatment. Current biomarkers for immunotherapy are limited, and there are hundreds of ongoing clinical trials assessing different treatment combinations with moderate clinical outcomes. Good biomarkers are desperately needed. Determining which patients will benefit from immunotherapy is vitally important for the treatment outcome, and financially crucial to avoid wasting precious healthcare resources.
The Solution
Founded on a commitment to improve patient outcomes, TechOnco developed the HealthCareProvider® platform, a groundbreaking plasma-based tool that leverages proteomic pattern recognition, bioinformatics, and AI to support and enhance clinical decision-making for oncologists.
⚫ Presentation
⚫ OurTake Analysis
Iraic's analysis, based on the information received from the company, is presented in the following sections.
I WANT TO INVEST